Generic name:coagulation factor viia-jncw (intravenous route) [ koh-a-gyoo-LAY-shun-FAK-tor-SEV-en-A-- jncw ]
Medically reviewed by Drugs.com. Last updated on Feb 28, 2022.
ThrombosisSerious arterial and venous thrombotic events may occur following administration of coagulation factor VIIa recombinant-jncw.Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive coagulation factor VIIa (recombinant)-jncw.Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis .
Commonly used brand name(s)
In the U.S.
- Sevenfact
Available Dosage Forms:
- Powder for Solution
Uses for Sevenfact
Coagulation factor VIIa-jncw is used to treat and prevent bleeding episodes in patients with Hemophilia A or B. Factor VIIa-jncw is a man-made protein produced to replicate the naturally occurring activated factor VII (factor VIIa) in the body. It is used to stop bleeding of injuries for patients with hemophilia by helping the blood to clot.
This medicine is to be given only by or under the direct supervision of your doctor.
Before using Sevenfact
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:
Allergies
Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Pediatric
Appropriate studies performed to date have not demonstrated pediatric-specific problems that would limit the usefulness of coagulation factor VIIa-jncw in children 12 years of age and older.
Geriatric
Adequate and well-controlled studies have not been done on the relationshi..
